Article
Oncology
Maria Gebre-Medhin, Eva Brun, Per Engstrom, Hedda Haugen Cange, Lalle Hammarstedt-Nordenvall, Johan Reizenstein, Jan Nyman, Edvard Abel, Signe Friesland, Helena Sjodin, Henrik Carlsson, Karin Soderkvist, Marcus Thomasson, Bjorn Zackrisson, Per Nilsson
Summary: The study demonstrates that for patients with locoregionally advanced HNSCC, cisplatin is superior to cetuximab in terms of locoregional control when used in combination with radiotherapy.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Review
Oncology
Sangwoo S. Kim, Hannah C. Liu, Loren K. Mell
Summary: Significant advancements have been made in the treatment of locally advanced head and neck cancer, particularly with the integration of concurrent chemotherapy and radiation therapy. Cisplatin, the most studied chemotherapeutic, may not be suitable due to pre-existing medical comorbidities and its toxicity. Efforts are being made to identify high-risk patients and explore alternative systemic agents such as targeted therapies and immunotherapies for cisplatin-ineligible patients, with the aim of improving outcomes and reducing adverse effects.
CURRENT TREATMENT OPTIONS IN ONCOLOGY
(2023)
Article
Oncology
Ting Liu, Li-Ting Liu, Jie-Yi Lin, Bo-Wen Shen, Shan-Shan Guo, Sai-Lan Liu, Xue-Song Sun, Yu-Jing Liang, Mei-Juan Luo, Xiao-Yun Li, Qiu-Yan Chen, Lin-Quan Tang, Hai-Qiang Mai
Summary: In locoregionally advanced nasopharyngeal carcinoma patients, the re-induction strategy with additional cycles of an alternative chemotherapy regimen before radiotherapy did not significantly improve tumor control and long-term survival compared to direct to radiotherapy strategy. Re-induction therapy led to worse locoregional relapse-free survival and progression-free survival, along with increased hematological toxicities.
RADIOTHERAPY AND ONCOLOGY
(2021)
Article
Oncology
Juan A. Marin-Jimenez, Marc Oliva, Paloma Peinado Martin, Santiago Cabezas-Camarero, Maria Plana Serrahima, Gonzalo Vazquez Masedo, Alicia Lozano Borbalas, Maria N. Cabrera Martin, Anna Esteve, Maria C. Iglesias Moreno, Esther Vilajosana Altamis, Lorena Arribas Hortiguela, Miren Taberna Sanz, Pedro Perez-Segura, Ricard Mesia
Summary: This study retrospectively analyzed the treatment options for patients with advanced head and neck squamous cell carcinoma who were unfit for cisplatin chemotherapy. The use of paclitaxel and cetuximab as induction chemotherapy was found to be an effective and well-tolerated option for these patients.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Renata Ferrarotto, Moran Amit, Priyadharsini Nagarajan, M. Laura Rubin, Ying Yuan, Diana Bell, Adel K. El-Naggar, Jason M. Johnson, William H. Morrison, David Rosenthal, Bonnie S. Glisson, Faye M. Johnson, Charles Lu, Frank E. Mott, Bita Esmaeli, Eduardo M. Diaz, Paul W. Gidley, Ryan P. Goepfert, Carol M. Lewis, Randal S. Weber, Jennifer A. Wargo, Sreyashi Basu, Fei Duan, Shalini S. Yadav, Padmanee Sharma, James P. Allison, Jeffrey N. Myers, Neil D. Gross
Summary: Neoadjuvant immunotherapy in locoregionally advanced, resectable cutaneous squamous cell carcinoma of the head and neck is safe and effective, inducing a high pathologic response rate. Pathologic responses were associated with an inflamed tumor microenvironment.
CLINICAL CANCER RESEARCH
(2021)
Review
Oncology
Hoda Mahdavi
Summary: Locally advanced stages of squamous cancers of the head and neck (LAHNCs) have a high risk of local and systemic relapse. The addition of induction therapy to the standard concurrent chemoradiotherapy (CCRT) has been widely used but did not improve survival rates in unselected populations. The TPF induction regimen showed superiority but did not demonstrate a survival advantage over CCRT alone. Newer systemic therapy combinations are currently being tested to find more effective treatments for LAHNCs.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2023)
Article
Oncology
Sachin R. Jhawar, Marcelo Bonomi, Paul M. Harari
Summary: The Oncology Grand Rounds series aims to help readers apply the results of key studies in clinical practice, using case presentations, literature reviews, and treatment recommendations to enhance understanding of the latest developments in oncology.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Otorhinolaryngology
Wataru Okano, Ryuichi Hayashi, Kazuto Matsuura, Takeshi Shinozaki, Toshifumi Tomioka
Summary: The study indicates that targeted neck dissection (ND) after definitive chemoradiotherapy is an effective intervention for patients with cervical disease recurrence, showing promising survival rates and control rates.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
(2021)
Review
Oncology
Bi-Cheng Wang, Bo-Hua Kuang, Xin-Xiu Liu, Guo-He Lin, Quentin Liu
Summary: Different induction chemotherapeutic strategies have varying effects and risks on the survival outcomes of patients with locoregionally advanced nasopharyngeal carcinoma. Gemcitabine plus platinum and docetaxel combined with 5-fluorouracil plus platinum strategies were associated with the highest rates of overall survival. The objective response and disease control rates were high after the completion of induction chemotherapy.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Maureen Bernadach, Michel Lapeyre, Anne-Francoise Dillies, Jessica Miroir, Melanie Casile, Juliette Moreau, Ioana Molnar, Angeline Ginzac, Nathalie Pham-Dang, Nicolas Saroul, Xavier Durando, Julian Biau
Summary: The study investigated predictive factors of toxicity of induction chemotherapy with TPF in locally advanced head and neck cancers, finding that nutritional status and hepatic dysfunction are significant risk factors to consider in therapeutic decisions.
Article
Oncology
Ying Li, Jianping Bi, Guoliang Pi, Hanping He, Yanping Li, Dandan Zheng, Zecheng Wei, Guang Han
Summary: This study aimed to evaluate the optimal number of cycles of induction chemotherapy (IC) in locoregionally advanced nasopharyngeal carcinoma (LANPC) by quantifying the changes in tumor volumes. The results showed that the effects of IC cycles on tumor volume reduction varied for different tumor and lymph node types. Two cycles of IC were sufficient for tumor and retropharyngeal lymph node volume reduction, while three cycles were recommended for further reduction of cervical lymph node volume.
Review
Oncology
Katie L. Melder, Mathew Geltzeiler
Summary: Sinonasal malignancies are difficult to treat and usually require surgery and adjuvant radiation therapy. However, surgery for advanced disease can cause significant morbidity. Induction chemotherapy has become an important part of treatment in improving disease control and preserving organ function.
Article
Oncology
Xia Li, Qigen Fang, Wei Du, Xu Zhang, Liyuan Dai, Yongming Qiao
Summary: The addition of sintilimab to induction chemotherapy in locally advanced head and neck squamous cell carcinoma patients resulted in a significantly higher objective response rate and longer progression-free survival compared to chemotherapy alone. However, there was no significant difference in overall survival between the two groups. The incidence of grade 3 or higher acute toxicity was similar in both groups.
Article
Oncology
Rui Zou, Jing-Jing Yuan, Qiang Li, Jian-Wu Ding, Bing Liao, Zi-Wei Tu, Rong-Huan Hu, Dan Gong, Jia-Li Hu, Lei Zeng
Summary: The study analyzed the outcomes and toxicities of ICT followed by CCRT plus ACT in LA-NPC patients, and found that this treatment approach did not significantly improve DFS and OS compared to adding ICT to CCRT, with more acute adverse events. Longer-term clinical studies are needed to evaluate treatment outcomes and late toxicities.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Horace Cheuk-Wai Choi, Sik-Kwan Chan, Ka-On Lam, Sum-Yin Chan, Sze-Chun Chau, Dora Lai-Wan Kwong, To-Wai Leung, Mai-Yee Luk, Anne Wing-Mui Lee, Victor Ho-Fun Lee
Summary: This study aimed to compare the survival benefits of all available induction chemotherapy (IC) regimens followed by concurrent chemoradiotherapy (CCRT) in non-metastatic locoregionally advanced nasopharyngeal carcinoma (NPC) through a network meta-analysis. The results showed that DC, GP, and PX were the most efficacious IC regimens, with doublet and gemcitabine-based regimens demonstrating better survival benefits compared to triplet and taxane-based regimens.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Vanita Noronha, Aditya Dhanawat, Vijay Maruti Patil, Nandini Menon, Ajay Kumar Singh, Pankaj Chaturvedi, Prathamesh Pai, Devendra Chaukar, Sarbani Ghosh Laskar, Kumar Prabhash
Summary: Neo-adjuvant chemotherapy has shown long term survival benefits in patients with locally advanced oral cavity squamous cell carcinomas.
Article
Oncology
Andrea Costantino, Claudio Sampieri, Gian Marco Pace, Bianca Maria Festa, Luca Cerri, Giorgio Gregory Giordano, Michael Dale, Giuseppe Spriano, Giorgio Peretti, Armando De Virgilio
Summary: This study aimed to predict the necessity of enteral nutrition at 28 days after surgery in patients with head and neck cancers. The results showed that the machine learning models had optimistic accuracy in predicting the need for enteral nutrition, but had moderate sensitivity.
Article
Oncology
Lirui Zhang, Qiaoshi Xu, Zhien Feng
Summary: This study presents a comprehensive clinical, genomic, and transcriptomic analysis of primary ghost cell odontogenic carcinoma (GCOC). The results provide the first comprehensive molecular atlas for primary GCOC, including previously identified CTNNB1 mutation and novel alterations in MAP3K, EP300, and the 22q11.21 region. The transcriptome analysis reveals significant involvement of cytokine-cytokine receptor interaction and the PI3K-Akt signaling pathway. More GCOC cases should be compared to validate these findings for accurate clinical guidance.
Article
Oncology
Emily Capone, Vittoria Perrotti, Ilaria Cela, Rossano Lattanzio, Lucrezia Togni, Corrado Rubini, Vito Carlo Alberto Caponio, Lorenzo Lo Muzio, Martina Colasante, Francesco Giansanti, Rodolfo Ippoliti, Stefano Iacobelli, Michael J. Wick, Nicole Spardy Burr, Gianluca Sala
Summary: This study explores the potential of galectin-3 binding protein (LGALS3BP) as a novel target for antibody-drug conjugate (ADC) therapy in adenoid cystic carcinoma (ACC). The results show that LGALS3BP is highly expressed in ACC tissues and treatment with anti-LGALS3BP ADC leads to durable tumor growth inhibition in animal models.
Article
Oncology
Andrea Costantino, Claudio Sampieri, Piero Giuseppe Meliante, Armando De Virgilio, Se-Heon Kim
Summary: This study compares the outcomes of transoral resections using the da Vinci SP and da Vinci Xi systems for oropharyngeal squamous cell carcinoma (OPSCC). The results indicate that the da Vinci SP system has advantages in terms of reduced docking and console times, as well as improved rates of wide negative resection margins. However, there were no significant differences in complication rates or postoperative functional outcomes between the two systems.